Australia markets closed

Ascendis Pharma A/S (A71.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
130.00+3.00 (+2.36%)
As of 08:14AM CEST. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
266,718
266,718
51,174
7,778
6,953
Cost of revenue
44,395
44,395
12,137
3,523
0
Gross profit
222,323
222,323
39,037
4,255
6,953
Operating expenses
Research development
413,454
413,454
379,624
295,867
260,904
Selling general and administrative
264,410
264,410
221,227
160,180
76,669
Total operating expenses
677,864
677,864
600,851
456,047
337,573
Operating income or loss
-455,541
-455,541
-561,814
-451,792
-330,620
Interest expense
44,065
44,065
30,682
3,911
1,918
Total other income/expenses net
8,605
8,605
7,253
71,067
-88,448
Income before tax
-474,144
-474,144
-577,817
-383,944
-419,174
Income tax expense
7,303
7,303
5,377
-367
-219
Income from continuing operations
-481,447
-481,447
-583,194
-383,577
-418,955
Net income
-481,447
-481,447
-583,194
-383,577
-418,955
Net income available to common shareholders
-481,447
-481,447
-583,194
-383,577
-418,955
Basic EPS
-10.72
-8.55
-10.40
-7.00
-8.28
Diluted EPS
-10.72
-8.55
-10.40
-7.00
-8.28
Basic average shares
56,131
56,287
56,072
54,772
50,617
Diluted average shares
56,131
56,287
56,072
54,772
50,617